Allarity Therapeutics announces stenoparib dosing patent into 2045
The company describes 36 allowed claims for twice-daily treatment, with formal patent issuance scheduled for Nov. 24.

Patent protection into 2045 would cover twice-daily stenoparib treatment as Allarity Therapeutics, Inc. NASDAQALLR announced a U.S. dosing patent on Wednesday. The company says 36 allowed claims cover specified doses, schedules and uses in ovarian cancer and other solid tumours.
Allarity's Nov. 18 release calls the patent granted, while its cautionary section lists Nov. 24 as the scheduled issuance date. It identifies U.S. Patent No. 12,806,205 and application No. 18/606,590.
Allarity is a small clinical-stage cancer-drug developer with principal operations in Denmark and a U.S. business address in Florida.
Shares closed at US$0.84 on Nasdaq at 4:00 p.m. EST on Nov. 17, according to Google Finance's NASDAQALLR page. That close preceded the patent announcement.
Dosing Claims Accompany Diagnostic Protection
Allarity describes stenoparib as an oral inhibitor of PARP and tankyrase enzymes, with the latter linked to the WNT signalling pathway. The company says the patent covers twice-daily administration for advanced ovarian cancer and several other solid tumours.
The described claims also reach patients whose cancers have resisted earlier treatments, including other PARP inhibitors. Allarity says the protection applies to specified doses and treatment schedules used in its development program.
"Its coverage of our twice-daily dosing strategy is critical as this is the dosing regimen we intend to advance to pivotal trials," Allarity chief executive Thomas Jensen said in the release.
The dosing patent adds to an existing U.S. patent for Allarity's stenoparib-specific Drug Response Predictor companion diagnostic, according to the announcement. The test uses tumour gene-expression information to help select patients the company believes may benefit from the drug.
Read more: Telo Genomics discloses option for worldwide AI cancer-cell licence
The announced protection concerns the claimed treatment methods, with scope and enforceability identified as uncertainties in the release. The patent document itself was not independently reviewed, so the company's description of those claims is the basis for this account.
Read more: Geneoscopy settles Delaware litigation with Abbott's Exact Sciences
In its Nov. 13 financial update, Allarity reported US$24.1 million in cash and restricted cash at Sept. 30, including US$10 million that was restricted. Third-quarter research and development expenses included a US$3.2 million manufacturing charge for drug supply for a potential Phase 3 trial. The financial highlights give no cash-runway estimate.
Trials Continue Alongside Approved Treatments
The Nov. 18 announcement describes an ongoing Phase 2 ovarian cancer protocol that began enrolling in summer 2025. It initially enrolled patients with platinum-resistant disease or patients unable to receive platinum treatment.
Additional groups include patients with primary platinum-refractory disease and those whose disease can be assessed clinically but cannot be measured under standard tumour-response criteria. Allarity says these groups will be assessed separately from the original cohort.
A separate Phase 2 study combines stenoparib with temozolomide in relapsed small cell lung cancer at U.S. Department of Veterans Affairs sites. The Nov. 13 update says the VA fully funds that combination trial.
The commercial peer set includes GSK plc LONGSK NYSEGSK, whose Zejula product page describes maintenance treatment for selected adults with advanced ovarian cancer. That setting requires a response to first-line platinum chemotherapy and a BRCA abnormality or homologous recombination deficiency.
Zejula's page describes once-daily dosing, while Allarity's announcement concerns a twice-daily regimen. The different treatment settings prevent a direct efficacy comparison from these disclosures.
For sector context, the State Street SPDR S&P Biotech ETF NYSEARCAXBI was quoted at US$145.88 at 8:00 p.m. EST on Nov. 16, according to Google Finance. That observation also predates Allarity's patent news.
The Nov. 18 release gives no date for the next clinical readout and reports no new efficacy or safety results. Its next specified event is the scheduled Nov. 24 issuance of the patent covering the claimed dosing methods.
Adrian Kessler






